PREVALENCE AND CHARACTERISTICS OF NON-ALCOHOLIC FATTY LIVER DISEASE IN PATIENTS WITH FATTY LIVER DIAGNOSED BY ULTRASOUND

Tran Thi Khanh Tuong1, , Tran Kinh Thanh2, Au Nhat Huy3
1 Internal Medicine Department, Faculty of Medicine, Pham Ngoc Thach University of Medicine
2 People’s Hospital 115
3 Internal Medicine Department, Faculty of Medicine, Tan Tao University

Nội dung chính của bài viết

Tóm tắt

Objectives: To determine the prevalence and characteristics of non-alcoholic fatty liver disease (NAFLD), including steatosis and fibrosis, in patients with fatty liver detected by ultrasound. Methods: A cross-sectional study was conducted on 303 patients diagnosed with fatty liver by ultrasound at People’s Hospital 115 from August 2019 to October 2020. Steatosis and fibrosis were assessed using FibroScan, employing the controlled attenuation parameter (CAP) and liver stiffness measurements (LSM). Statistical analysis was performed using SPSS version 22.0. Results: The prevalence of NAFLD in patients with fatty liver detected by ultrasound and assessed by FibroScan using CAP probe was 66%. Among patients with fatty liver on ultrasound who have NAFLD, the distribution of liver fat levels was as follows: S1 = 20.5%; S2 = 27%; S3 = 52.5%. The stages of liver fibrosis were: F0 - F1 at 74.5%; significant fibrosis at 25.5%, advanced fibrosis at 11%, and cirrhosis at 6%. NAFLD patients exhibited higher body mass index (BMI), waist circumference, cholesterol, triglyceride, type 2 diabetes mellitus (T2DM), and obesity rates compared to those without NAFLD. Conclusion: The study underscores the high prevalence of NAFLD in patients with fatty liver detected by ultrasound, with the highest proportion of patients in stage S3, while 25.5% of the cases are classified as significant fibrosis, which indicates a considerable level of liver damage. 

Chi tiết bài viết

Tài liệu tham khảo

1. Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease: Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016; 64(1):73-84.
2. Younossi ZM, Rinella ME, Sanyal AJ, et al. From NAFLD to MAFLD: Implications of a change in terminology on disease recognition and epidemiology. Hepatology. 2024; 70(4):1234-1245.
3. Fan JG, Kim SU, Wong VW. New trends on obesity and NAFLD in Asia. J Hepatol. 2017; 67(4):862-873.
4. Wong V, Vergniol J, Wong G, Foucher J. Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. Hepatology. 2010; 5:454-462.
5. Rinella ME. Nonalcoholic fatty liver disease: A systematic review. JAMA. 2015; 313(22):2263-2273.
6. Smith A, Johnson B, Lee C, et al. Ultrasound indicators for hepatic steatosis: A clinical review. Radiology Journal. 2021; 45(6):789-795
7. Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic associated fatty liver disease: An international expert consensus statement. J Hepatol. 2022; 76(4):968-974.
8. Berger A, Shili S, Zuberbuhler F, et al. Liver stiffness measurement with fibroscan: Use the right probe in the right conditions! Clin Transl Gastroenterol. 2019; 10.
9. Powell EE, Wong VW, Rinella M. Non-alcoholic fatty liver disease. Lancet. 2023; 402(10409):2311-2322.
10. Anstee QM, Reeves HL, Kotsiliti E, et al. From NASH to HCC: Current concepts and future challenges. Nat Rev Gastroenterol Hepatol. 2023; 20(1):24-38.